Sequencing of charcot-marie-tooth disease genes in a toxic polyneuropathy

Annals of Neurology

Volumn 76, Issue 5, 2014, Pages 727-737

  Beutler, Andreas S ^a,b   Kulkarni, Amit A ^a   Kanwar, Rahul ^a   Klein, Christopher J ^a   Therneau, Terry M ^a,b   Qin, Rui ^a,b   Banck, Michaela S ^a,b   Boora, Ganesh K ^a   Ruddy, Kathryn J ^a,b   Wu, Yanhong ^a   Smalley, Regenia L ^a   Cunningham, Julie M ^a   Le Lindqwister, Nguyet Anh ^c   Beyerlein, Peter ^d   Schroth, Gary P ^e   Windebank, Anthony J ^a   Züchner, Stephan ^f   Loprinzi, Charles L ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c Illinois Oncology Research Association Community Clinical Oncology Program IL Cancer Care   (United States)

^d TECHNICAL UNIVERSITY OF APPLIED SCIENCES WILDAU   (Germany)

^e ILLUMINA INC   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GENOMIC DNA; PACLITAXEL; ANTINEOPLASTIC AGENT; ARHGEF10 PROTEIN, HUMAN; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR;

ADULT; ALLELE; ARHGEF10 GENE; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CONTROLLED STUDY; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL NEUROPATHY; PHENOTYPE; POLYNEUROPATHY; PRX GENE; RISK FACTOR; SINGLE NUCLEOTIDE VARIANT; TOXIC POLYNEUROPATHY; CHEMICALLY INDUCED; COMPLICATION; GENETICS; MIDDLE AGED; MUTATION; NEOPLASM; PROSPECTIVE STUDY;

ALLELES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHARCOT-MARIE-TOOTH DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PACLITAXEL; POLYNEUROPATHIES; PROSPECTIVE STUDIES; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS;

EID: 84912102998     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24265     Document Type: Article

References (42)

1. Klein CJ, Duan X, Shy ME. Inherited neuropathies: clinical overview and update. Muscle Nerve 2013;48:604-622.
2. Saporta AS, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011; 69:22-33.
3. Zuchner S, Vance JM. Mechanisms of disease: a molecular genetic update on hereditary axonal neuropathies. Nat Clin Pract Neurol 2006;2:45-53.
4. Timmerman V, Strickland AV, Zuchner S. Genetics of Charcot-Marie-Tooth (CMT) disease within the frame of the Human Genome Project success. Genes (Basel) 2014;5:13-32.
5. Klein CJ, Middha S, Duan X, et al. Application of whole exome sequencing in undiagnosed inherited polyneuropathies. J Neurol Neurosurg Psychiatry [Epub ahead of print].
6. Dickerhoff R, Lindner W, Scheiber W. Severe vincristine neurotoxicity in a patient with Charcot-Marie-Tooth disease. Pediatr Hematol Oncol 1988;5:61-64.
7. Graf WD, Chance PF, Lensch MW, et al. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer 1996;77: 1356-1362.
8. Hogan-Dann CM, Fellmeth WG, McGuire SA, Kiley VA. Polyneuropathy following vincristine therapy in two patients with Charcot-Marie-Tooth syndrome. JAMA 1984;252:2862-2863.
9. Naumann R, Mohm J, Reuner U, et al. Early recognition of hereditary motor and sensory neuropathy type 1 can avoid lifethreatening vincristine neurotoxicity. Br J Haematol 2001;115:323-325.
10. Mercuri E, Poulton J, Buck J, et al. Vincristine treatment revealing asymptomatic hereditary motor sensory neuropathy type 1A. Arch Dis Child 1999;81:442-443.
11. Nakamura T, Hashiguchi A, Suzuki S, et al. Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation. Neurogenetics 2012;13:77-82.
12. Neumann Y, Toren A, Rechavi G, et al. Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease. Med Pediatr Oncol 1996;26:280-283.
13. Olek MJ, Bordeaux B, Leshner RT. Charcot-Marie-Tooth disease type I diagnosed in a 5-year-old boy after vincristine neurotoxicity, resulting in maternal diagnosis. J Am Osteopath Assoc 1999;99: 165-167.
14. Chauvenet AR, Shashi V, Selsky C, et al. Vincristine-induced neuropathy as the initial presentation of Charcot-Marie-Tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003;25:316-320.
15. Postma TJ, Aaronson NK, Heimans JJ, et al. The development of an EORTC quality of life questionnaire to assess chemotherapyinduced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 2005;41:1135-1139.
16. Lavoie Smith EM, Barton DL, Qin R, et al. Assessing patientreported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 2013;22:2787-2799.
17. Cavaletti G, Cornblath DR, Merkies IS, et al. The chemotherapyinduced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 2013;24:454-462.
18. Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011;29:1472-1478.
19. Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 2012;118:5171-5178.
20. Rasch G. Probabilistic models for some intelligence and attainment tests. Expanded ed. Chicago, IL: University of Chicago Press, 1980.
21. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-1303.
22. Cingolani P, Platts A, Wang le L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 2012;6:80-92.
23. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic acids Res 2010;38:e164.
24. Zuchner S, Mersiyanova IV, Muglia M, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004;36:449-451.
25. Bissar-Tadmouri N, Nelis E, Zuchner S, et al. Absence of KIF1B mutation in a large Turkish CMT2A family suggests involvement of a second gene. Neurology 2004;62:1522-1525.
26. Neale BM, Rivas MA, Voight BF, et al. Testing for an unusual distribution of rare variants. PLoS Genet 2011;7:e1001322.
27. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010;7: 248-249.
28. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009;4:1073-1081.
29. Guilbot A, Williams A, Ravise N, et al. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Hum Mol Genet 2001;10:415-421.
30. Takashima H, Boerkoel CF, De Jonghe P, et al. Periaxin mutations cause a broad spectrum of demyelinating neuropathies. Ann Neurol 2002;51:709-715.
31. Kabzinska D, Drac H, Sherman DL, et al. Charcot-Marie-Tooth type 4F disease caused by S399fsx410 mutation in the PRX gene. Neurology 2006;66:745-747.
32. Barankova L, Siskova D, Huhne K, et al. A 71-nucleotide deletion in the periaxin gene in a Romani patient with early-onset slowly progressive demyelinating CMT. Eur J Neurol 2008;15:548-551.
33. Nouioua S, Hamadouche T, Funalot B, et al. Novel mutations in the PRX and the MTMR2 genes are responsible for unusual Charcot-Marie-Tooth disease phenotypes. Neuromusc Disord 2011;21:543-550.
34. Goldstein DB, Allen A, Keebler J, et al. Sequencing studies in human genetics: design and interpretation. Nat Rev Genet 2013; 14:460-470.
35. Altekruse SF, Korsary C, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute, 2010. Available at: http://seer.cancer.gov/archive/csr/1975-2007/. Accessed February 18, 2014.
36. Matsuda T, Ajiki W, Marugame T, et al. Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological and international comparative study. Jpn J Clin Oncol 2011;41:40-51.
37. Alberti P, Rossi E, Cornblath DR, et al. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 2014;25:257-264.
38. Dyck PJ, Overland CJ, Low PA, et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial. Muscle Nerve 2010;42:157-164.
39. Gillespie CS, Sherman DL, Fleetwood-Walker SM, et al. Peripheral demyelination and neuropathic pain behavior in periaxin-deficient mice. Neuron 2000;26:523-531.
40. Chaya T, Shibata S, Tokuhara Y, et al. Identification of a negative regulatory region for the exchange activity and characterization of T332I mutant of Rho guanine nucleotide exchange factor 10 (ARHGEF10). J Biol Chem 2011;286:29511-29520.
41. Verhoeven K, De Jonghe P, Van de Putte T, et al. Slowed conduction and thin myelination of peripheral nerves associated with mutant rho guanine-nucleotide exchange factor 10. Am J Hum Genet 2003;73:926-932.
42. Tokunaga S, Hashiguchi A, Yoshimura A, et al. Late-onset Charcot-Marie-Tooth disease 4F caused by periaxin gene mutation. Neurogenetics 2012;13:359-365.